Published in Anticancer Res on August 28, 2008
The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle (2012) 1.10
Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS One (2013) 0.96
The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle (2014) 0.94
Prediction of disease genes using tissue-specified gene-gene network. BMC Syst Biol (2014) 0.91
Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget (2015) 0.82
Inference of causal networks from time-varying transcriptome data via sparse coding. PLoS One (2012) 0.78
SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet (1998) 3.79
Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature (1983) 2.77
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst (1999) 1.73
Mutagenicity of carcinogenic methylating agents is associated with a specific DNA modification. Nature (1980) 1.71
Telomere length abnormalities in mammalian radiosensitive cells. Cancer Res (2001) 1.54
Exceptional mutagenicity of a benzo(a)pyrene diol epoxide in cultured mammalian cells. Nature (1976) 1.40
Human acrocentric chromosomes with transcriptionally silent nucleolar organizer regions associate with nucleoli. EMBO J (2001) 1.35
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J (1999) 1.29
Skin and fat necrosis of the breast following methylene blue dye injection for sentinel node biopsy in a patient with breast cancer. Int Semin Surg Oncol (2005) 1.26
Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. Nature (1982) 1.26
Oncological safety and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction. Surg Oncol (2008) 1.23
A novel syndrome affecting multiple mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-2p13. Am J Hum Genet (2001) 1.22
Construction and characterization of a highly stable human: rodent monochromosomal hybrid panel for genetic complementation and genome mapping studies. Cytogenet Cell Genet (1995) 1.21
The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer (2009) 1.20
WNT5A expression in human breast cancer. Anticancer Res (2005) 1.18
Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res (2001) 1.18
hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol (2003) 1.13
hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat (2003) 1.04
Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. Oncogene (1997) 1.02
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res (2007) 1.01
Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J Natl Cancer Inst (2001) 0.98
Management of gynaecomastia: an update. Int J Clin Pract (2007) 0.97
The prevention of breast cancer: an overview. Curr Med Res Opin (2001) 0.97
Mechanisms involved in the immortalization of mammalian cells by ionizing radiation and chemical carcinogens. Carcinogenesis (1995) 0.96
Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. Anticancer Res (2010) 0.96
The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol (2001) 0.94
Breast papillomas: current management with a focus on a new diagnostic and therapeutic modality. Int Semin Surg Oncol (2006) 0.94
The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am J Surg (1999) 0.93
Mammographic breast density by area of residence: possible evidence of higher density in urban areas. Curr Med Res Opin (2008) 0.92
Telomerase activity and lymphovascular invasion in breast cancer. Eur J Surg Oncol (2000) 0.92
Evidence for the management of mastalgia. Curr Med Res Opin (2004) 0.90
Control of aromatase activity in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol (1997) 0.88
The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol (2002) 0.88
Screening mammography in women aged 40-49: is it time to change? Int Semin Surg Oncol (2006) 0.88
Does post-mastectomy radiotherapy represent a contraindication to skin-sparing mastectomy and immediate reconstruction: an update. Surg Oncol (2012) 0.87
Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer (1999) 0.87
Does mammary ductoscopy have a role in clinical practice? Int Semin Surg Oncol (2006) 0.87
Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene (2012) 0.87
Cell-mediated mutagenesis in cultured Chinese hamster cells by carcinogenic polycyclic hydrocarbons: nature and extent of the associated hydrocarbon-DNA reaction. Mutat Res (1977) 0.86
Benzo(a)pyrene metabolism and DNA adduct formation in serially cultivated strains of human epidermal keratinocytes. Int J Cancer (1980) 0.86
Oncological considerations of skin-sparing mastectomy. Int Semin Surg Oncol (2006) 0.86
Telomere-dependent senescence. Nat Biotechnol (1999) 0.86
Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med (2006) 0.85
The cytotoxic, mutagenic and clastogenic effects of chromium-containing compounds on mammalian cells in culture. Mutat Res (1979) 0.85
Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res (2006) 0.85
Clinical impact of lymph node status in rectal cancer. Surg Oncol (2011) 0.85
The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol (2005) 0.84
Inhibition of metabolic cooperation between mammalian cells in culture by tumor promoters. Carcinogenesis (1981) 0.84
Identification of human tumour suppressor genes by monochromosome transfer: rapid growth-arrest response mapped to 9p21 is mediated solely by the cyclin-D-dependent kinase inhibitor gene, CDKN2A (p16INK4A). Carcinogenesis (1996) 0.84
The evolving role of radiofrequency ablation therapy of breast lesions. Anticancer Res (2010) 0.83
Core biopsy is accurate in determining the hormone receptor status of early breast cancer. Am J Surg (2004) 0.83
Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol (2005) 0.83
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Treat (2006) 0.83
Surgical excision for B3 breast lesions diagnosed by vacuum-assisted core biopsy. Anticancer Res (2010) 0.83
hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. Anticancer Res (2007) 0.82
The utility of MRI for the screening and staging of breast cancer. Int J Clin Pract (2008) 0.82
Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol (2001) 0.82
Is MRI more accurate than CT in estimating the real size of adrenal tumours? Eur J Surg Oncol (2001) 0.82
Abdominal ganglioneuromas in adults. Urol Int (2003) 0.82
Pure antiestrogens and breast cancer. Curr Med Res Opin (2001) 0.82
Evidence of a tumour suppressor function for DLEC1 in human breast cancer. Anticancer Res (2010) 0.81
A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization. Oncogene (1998) 0.81
Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol (2007) 0.81
Management of desmoid tumours including a case report of toremifene. Ann Oncol (1994) 0.81
Evidence for a pro-apoptotic function of RACK1 in human breast cancer. Oncogene (2010) 0.80
Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer. Oncol Rep (2013) 0.80
Localization of a novel tumor metastasis suppressor region on the short arm of human chromosome 2. Genes Chromosomes Cancer (2000) 0.80
Identification of tumor metastasis suppressor region on the short arm of human chromosome 20. Genes Chromosomes Cancer (2001) 0.80
Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res (2007) 0.80
Genetic and functional analyses exclude mortality factor 4 (MORF4) as a keratinocyte senescence gene. Cancer Res (1999) 0.80
Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res (1998) 0.80
Telomerase activity and Bcl-2 expression in human breast cancer. Eur J Surg Oncol (2002) 0.80
The effect of different TP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. Genes Chromosomes Cancer (1997) 0.80
Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma. Cancer Res (1999) 0.80
Novel use of a selectable fusion gene as an "in-out" marker for studying genetic loss in mammalian cells. Mol Carcinog (1995) 0.79
Telomerase activity and prognosis in breast cancer. Eur J Surg Oncol (1999) 0.79
Multistep malignant transformation of mammalian cells by carcinogens: induction of immortality as a key event. Carcinog Compr Surv (1985) 0.79
Radial scars and breast cancer. N Engl J Med (1999) 0.79
The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer. Anticancer Res (2007) 0.79
Telomerase activity in phyllodes tumours. Eur J Surg Oncol (1999) 0.79
Cell-mediated mutagenesis in cultured Chinese hamster cells by polycyclic hydrocarbons: mutagenicity and DNA reaction related to carcinogenicity in a series of compounds. Int J Cancer (1979) 0.78
Hot-water bottle induced thermal injury of the skin overlying Becker's mammary prosthesis. Breast (1999) 0.78
Morphological transformation of immortalized hamster dermal fibroblasts following treatment with simple alkylating carcinogens. Carcinogenesis (1988) 0.78
Herceptin and breast cancer: an overview for surgeons. Surg Oncol (2008) 0.78
Dairy products and breast cancer risk: a review of the literature. Int J Fertil Womens Med (2006) 0.78
HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR. Anticancer Res (2007) 0.78
hTERT protein expression is independent of clinicopathological parameters and c-Myc protein expression in human breast cancer. J Carcinog (2005) 0.78
A quantitative comparison of the mutagenicity of carcinogenic polycyclic hydrocarbon derivatives in cultured mammalian cells. Int J Cancer (1979) 0.78
The evolving role of sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol (2003) 0.78